Takeda partnered with Evox Therapeutics in a deal worth $882 million to develop up to five rare disease programs, Pharmaphorum reports.
What you should know:
1. Takeda provided Evox with $44 million upfront.
2. Evox will develop protein replacement and mRNA therapies that will use Oxford University's exosome delivery platform. The company is currently developing a candidate for Niemann-Pick disease type C and a second undisclosed program, and it could develop up to three more rare disease candidates through the partnership.
3. Takeda will gain rights to any therapies Evox develops, taking them over at the clinical development stage.